NCT00217594View on ClinicalTrials.gov

A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 21, 2005

Primary Completion Date

February 6, 2017

Study Completion Date

February 6, 2017

Conditions
Myelodysplastic Syndromes
Interventions
DRUG

Alemtuzumab (Campath)

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH

NCT00217594 - A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome | Biotech Hunter | Biotech Hunter